Neoantigen Targeted Therapies Market, 2019-2030

Wednesday, July 24, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, July 24, 2019 /PRNewswire/ --

INTRODUCTIONCancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such

as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers. Moreover, the non-specific and highly toxic nature of chemotherapy and radiation therapy, have severe detrimental effects on patients' quality of life. Amongst the targeted anti-cancer therapies, immunotherapy has emerged as a potent option, capable of eliminating tumor cells with minimal side effects. For instance, the introduction of the immune check point inhibitors (such as PD-1/PD-L1 and CTLA-4 inhibitors) enabled healthcare providers to offer long term clinical benefit to patients suffering from metastatic tumors. However, these therapies have been reported to generate variable / inconsistent immune responses across different patients and, as a result, only a fraction of patients have actually ended up benefiting from such treatments. In fact, it is estimated that close to 70% of treated patients do not respond to single-agent immune checkpoint therapy.Read the full report: https://www.reportlinker.com/p05797103/?utm_source=PRN Recent developments in genomic analysis and advances in bioinformatics have enabled the adoption of more personalized treatment approaches, such as neoantigen targeted therapies. Cancer neoantigens is a term used to refer to a subset of antigens encoded by tumor-specific, mutated genes, which have not previously been recognized by host's immune system. These are considered to be potential biological targets that can be used to augment the therapeutic value of a number of cancer immunotherapies, including immune checkpoint inhibitors and cancer vaccines, having demonstrated the capability to elicit strong T-cell mediated immune response. Currently, several neoantigen-based therapies are being investigated in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab and nivolumab. In fact, multiple such initiatives by start-ups are backed by venture capital firms and other strategic investors.SCOPE OF THE REPORTThe "Neoantigen Targeted Therapies Market, 2019-2030" report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.An in-depth analysis of the various patents that have been filed / granted related to neoantigens till April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.One of the key objectives of the report was to estimate the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others) [B] type of treatment (personalized and off-the-shelf), [C] type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), [D] route of administration (intradermal, intravenous, subcutaneous, and others) and [E] key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):Gabriel Nistor (Chief Scientific Officer, AIVITA Biomedical)Ella Sorani (Vice President Research and Development, BioLineRx)Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM)All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.The secondary sources of information includeAnnual reportsInvestor presentationsSEC filingsIndustry databasesNews releases from company websitesGovernment policy documentsIndustry analysts' viewsWhile the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.CHAPTER OUTLINESChapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for neoantigen targeted therapies, in the short-mid term and long term.Chapter 3 provides a general overview of neoantigen targeted therapies, featuring brief descriptions of the various conventional forms of therapy that are used for the treatment of oncological disorders. It also includes a discussion on the advent and evolution of cancer immunotherapy, while highlighting its limitations. The chapter lays emphasis on the role of neoantigens in cancer immunotherapy, providing details on the various types of neoantigens, product development-related aspects of neoantigen targeted therapies and the diverse strategies that are available / being investigated for delivery of neoantigen-based therapeutics.Chapter 4 includes information on nearly 150 molecules that are currently under development for the treatment of various cancer indications. It features a comprehensive analysis of pipeline molecules, highlighting phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer. In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.Chapter 5 provides detailed profiles of some of the leading stakeholders in this field (shortlisted on the basis of number of pipeline products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent collaborations and an informed future outlook.Chapter 6 provides a detailed analysis of close to 300 research articles related to neoantigen targeted therapies, published in the period 2015-2019 (till February). The analysis takes into consideration several aspects, namely target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period), within this domain.Chapter 7 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to neoantigens. For this analysis, we looked at the patents that have been published by various players, till April 2019. The analysis highlights key details and trends associated with these patents, including patent type (granted patents, patent applications and others), publication year, patent issuing authorities / patent offices (USPTO, WIPO, APO, EPO and others), CPC classification, emerging focus areas and the leading industry / academic players. The chapter also includes a patent benchmarking analysis and a detailed valuation analysis.Chapter 8 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2014. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, distribution and supply agreements, service alliances and other agreements) that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting most popular therapies and disease indications.Chapter 9 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till April 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of neoantigen targeted therapies till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target indications (bone and cartilage cancer, colorectal cancer, head and neck cancer, renal carcinoma, hepatocellular carcinoma, lung cancer, gynecological cancer and others), type of treatment (personalized and off-the-shelf), type of immunotherapy (dendritic cell vaccine, DNA / RNA-based vaccine, protein / peptide-based vaccine and TIL-based therapy), route of administration (intradermal, intravenous, subcutaneous, and others) and key geographical regions (US, EU5 and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the neoantigen targeted therapies industry.Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company name) Gabriel Nistor (Chief Scientific Officer, AIVITA Biomedical), Ella Sorani (Vice President Research and Development, BioLineRx) and Heinz Lubenau (Chief Operating Officer and Co-Founder, VAXIMM).Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.Read the full report: https://www.reportlinker.com/p05797103/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/neoantigen-targeted-therapies-market-2019-2030-300890201.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store